Guided Therapeutics Receives New Half Million Dollar Purchase Order from China

Rhea-AI Summary

Guided Therapeutics (OTCQB: GTHP) announced a new purchase order worth $530,695 from its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). This order follows a larger existing order of $2.5 million. The new order indicates progress towards FDA approval of LuViva, expected in early 2022. Guided Therapeutics anticipates revenues from China to exceed $1 million in 2021. Cervical cancer remains a significant health issue in China, highlighting the potential market for their advanced detection technology.

Positive

• Received a new purchase order of $530,695 from SMI, indicating progress in the approval process.
• Existing order of $2.5 million underscores strong market interest.
• Forecasting over $1 million in revenues from China for 2021, showing growth potential.

Negative

• Approval timeline for LuViva in China extends to early 2022, indicating potential delays.
• Risks associated with FDA approval and market acceptance may affect future revenue.

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today that it had received a new purchase order in the amount of $530,695 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI). The new purchase order, which was issued by SMI based on its progress with the Chinese FDA for approval of LuViva, stipulates a 10% down payment in January 2021 with the balance to be paid in May 2021. This new order is in addition to an existing larger order of $2.5 Million, a quarter of which is due upon filing an application with the Chinese FDA and the balance due upon approval by Chinese FDA. The filing is expected in the third quarter of 2021 with approval expected early in 2022.

“We are extremely pleased with the progress that we are making with SMI in China, the world’s second largest medical device market,” said Gene Cartwright, CEO of Guided Therapeutics. “The new purchase order is tangible evidence that SMI is working its way toward approval of LuViva in China. We feel confident in forecasting that revenues from China alone in 2021 will exceed a million dollars.”

According to the World Health Organization, cervical cancer is ranked as one of the most frequent cancers in women in the world and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing cervical cancer. Current estimates indicate approximately 100,000 new cases of cervical cancer are diagnosed each year and 30,000 deaths occur annually due to cervical cancer in China.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent filings.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005050/en/

FAQ

What is the new purchase order amount announced by Guided Therapeutics on January 5, 2021?

Guided Therapeutics announced a new purchase order amounting to $530,695 from Shandong Yaohua Medical Instrument Corporation.

What is the significance of the purchase order from SMI for GTHP?

The purchase order signifies progress towards FDA approval for the LuViva device in China, vital for GTHP's market expansion.

When is the FDA filing for LuViva expected?

The FDA filing for LuViva is expected in the third quarter of 2021.

How much revenue does Guided Therapeutics forecast from China in 2021?

Guided Therapeutics forecasts revenues from China to exceed $1 million in 2021.